Recent scientific exploration into psychedelics provides evidence that these powerful substances can profoundly reshape human ...
TUNE in, drop out… and clock on. Workers in Silicon Valley and elsewhere have long extolled the virtues of LSD and other psychedelics. Small doses, they say, make them more productive, focused and ...
A new analysis of brain imaging data reveals that lysergic acid diethylamide, commonly known as LSD, reduces the ...
Years ago, LSD was seen as the evil stepchild of drugs. Today, research indicates LSD may treat anxiety and depression, and ...
Share on Pinterest The use of psychedelic drugs such as LSD in mental health treatment is at the forefront of clinical research. Lyuba Burakova/Stocksy Psychedelic compounds have gained increased ...
Researchers from Imperial College London, working with the Beckley Foundation, have for the first time visualised the effects of LSD on the human brain. In a series of experiments, scientists have ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. It's always been a bit of a mystery why LSD is such a potent ...
In large doses, lysergic acid diethylamide (LSD) can repair damaged neurons in the brain, and reveal new ways of seeing the world. In small doses, microdosers chase the effects of the drug on ...
The drug, as well as a placebo, was given to 20 healthy volunteers with previous experience taking psychedelics. Their brains were then imaged inside an fMRI scanner to visualize their brain activity.
This post has been corrected, as indicated below. For the first time in more than four decades, the drug lysergic acid diethylamide -- better known as LSD -- has been the experimental adjunct to ...
With LSD finally gaining mainstream acceptance — just last month, the FDA granted breakthrough status to an LSD formula to treat anxiety — author Norman Ohler investigates how it took so long for the ...
Definium Therapeutics said a single dose of its LSD-based experimental pill ​significantly reduced symptoms of major depression in patients in a late-stage ‌trial, sending its shares soaring 55% to a ...